Kamau Therapeutics
Vali Barsan is an attending physician in oncology at Stanford University School of Medicine, with clinical expertise in leukemia, lymphoma, molecular diagnostic testing for relapsed cancers, and cancer immunotherapy Phase I trials. Currently involved in multiple roles, Vali Barsan serves as a clinical fellow at Kamau Therapeutics, and holds board director positions at ArsenalBio, Neuron23, Umoja Biopharma, and Karius, among others, focusing on innovative cancer treatment and precision medicine. Previous experience includes medical consulting roles at Illumina and Karius, as well as graduate research at MD Anderson Cancer Center. Vali Barsan's education includes a fellowship in Pediatric Hematology/Oncology and Stem Cell Transplantation from Stanford, a residency in Pediatrics, and an M.D. from Baylor College of Medicine, alongside a B.S. in Bioengineering from UC San Diego.
This person is not in any teams
This person is not in any offices
Kamau Therapeutics
Kamau Therapeutics is a clinical-stage, next-generation gene correction company harnessing high efficiency targeted gene integration to develop a new class of therapies with the aim to cure a wide range of serious and life-threatening diseases. Our novel gene correction approach, called homology-directed repair (HDR), overcomes prior limitations in specificity, efficiency, and durability of gene editing to offer broad potential for transforming human health outcomes through the delivery of one-time curative cell therapies. Our platform aims treat or cure a range of serious genetic diseases with unmet medical needs.